Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2019-07-09 Director's Dealing
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is clearly identified as an 'RNS Number' announcement from 'Oxford BioDynamics PLC' dated '09 July 2019'. The content details 'PDMR Dealing' (Persons Discharging Managerial Responsibilities) transactions, specifically the purchase of Ordinary Shares by the CEO and CFO, and provides detailed tables conforming to EU Market Abuse Regulation requirements for insider transactions. This type of filing, reporting insider trades by directors/executives, directly matches the definition for Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2019-07-09 English
OBD appoints Dr Bartu Ahiska
Board/Management Information Classification · 98% confidence The document is a formal announcement disseminated via RNS (RNS Number : 0272C) on June 13, 2019. The core content announces the appointment of a new executive, Dr Bartu Ahiska, as Senior Vice President (Commercial). This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. Although it is distributed via RNS, the specific subject matter is management change, making MANG the most precise classification over the general RNS fallback.
2019-06-13 English
PDMR Dealing / Grant of Share Options
Director's Dealing Classification · 100% confidence The document is clearly identified as an 'RNS Number : 8887B' announcement from the London Stock Exchange's news service. The content details the 'Grant of Share Options' to Non-Executive Directors (PDMR Dealing) and provides the required regulatory tables detailing the transaction under the EU Market Abuse Regulation. This type of announcement, which reports personal share transactions by directors, directly corresponds to the definition of Director's Dealing (DIRS). Although it originates from RNS, the specific nature of the content (insider trade/director dealing) makes DIRS the most accurate classification over the general RNS fallback.
2019-06-12 English
Board Transition
Board/Management Information Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the stepping down of a Non-Executive Director (Alison Kibble) and updates the membership of board sub-committees. This type of announcement, concerning changes in the board of directors or senior management, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the primary subject matter is management change, making MANG the most specific classification. The document length (4475 chars) is not indicative of a full report, but the content is specific enough to avoid the general RNS fallback.
2019-05-31 English
Interim Results for 6 months ended 31 March 2019
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Results' announcement for Oxford BioDynamics PLC for the six-month period ended 31 March 2019. It contains financial highlights (revenue, operating loss, cash position), operational updates, and management commentary. While it is titled 'Interim Results', it is formatted as an RNS (Regulatory News Service) announcement, which is the standard method for UK-listed companies to release their interim financial results to the market. According to the classification rules, this constitutes an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2019
2019-05-28 English
OBD joins ALS Biomarker study sponsored by MTPA
Environmental & Social Information Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content describes Oxford BioDynamics Plc noting an announcement by Mitsubishi Tanabe Pharma America regarding OBD joining a biomarker study (REFINE-ALS). This is a general corporate update concerning a collaboration and scientific development, not a formal financial report (like 10-K or IR), a specific shareholder vote result (DVA), or a management change (MANG). Since it is a general, non-specific regulatory news release that doesn't fit the other defined categories (like ER, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length is substantial enough (7960 chars) that it is the primary announcement itself, not just a brief notice about a report being attached (which would suggest RPA).
2019-05-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.